LeapZipBlog: Steve Blade's blog: Lung Cancer Diagnostics Market Analysis and Demand with Forecast Overview 2017 to 2022

Lung Cancer Diagnostics Market Analysis and Demand with Forecast Overview 2017 to 2022

August 16, 2019 by Steve Blade  

Growth of the global lung cancer diagnostics market is mainly attributed to surging developments in the lung cancer-specific biomarkers. Diagnostic tools, such as these, will facilitate personalized treatment approach for lung malignancies. Numerous biomarkers are in the research pipeline. Epigenomics AG has launched a new test which is based on blood by utilizing DNA methylation biomarkers, and their developments are in process. Initial results of these tests have guaranteed early diagnosis of lung cancer. These incidences are most likely to increase demand for diagnosis of lung cancer across the globe.

Request Sample Report:

https://www.factmr.com/connectus/sample?flag=S&rep_id=49

Table of Content

Chapter 1. Global Lung Cancer Diagnostics Market - Executive Summary. 12

Chapter 2. Global Lung Cancer Diagnostics Market Overview. 14
2.1. Introduction. 14
       2.1.1. Global Lung Cancer Diagnostics Market Taxonomy. 14
       2.1.2. Global Lung Cancer Diagnostics Market Definition. 14
2.2. Global Lung Cancer Diagnostics Market Size (US$ Mn) and Forecast, 2012-2022. 15
       2.2.1. Global Lung Cancer Diagnostics Market Y-o-Y Growth. 15
2.3. Global Lung Cancer Diagnostics Market Dynamics. 15
       2.3.1. Drivers. 15
       2.3.2. Restraints. 15
       2.3.3. Trends. 16
2.4. Supply Chain. 16
2.5. Key Participants Market Presence (Intensity Map) By Region. 16

Chapter 3. Global Lung Cancer Diagnostics Market Analysis and Forecast By Test Type. 17
3.1. Global Lung Cancer Diagnostics Market Size and Forecast By Test Type, 2012-2022. 17
       3.1.1. CA Test Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 17
                3.1.1.1. Revenue (US$ Mn) Comparison, By Region. 17
                3.1.1.2. Market Share Comparison, By Region. 19
                3.1.1.3. Y-o-Y growth Comparison, By Region. 19
       3.1.2. HER2 Tests Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 20
                3.1.2.1. Revenue (US$ Mn) Comparison, By Region. 20
                3.1.2.2. Market Share Comparison, By Region. 22
                3.1.2.3. Y-o-Y growth Comparison, By Region. 22
       3.1.3. ALK Tests Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 23
                3.1.3.1. Revenue (US$ Mn) Comparison, By Region. 23
                3.1.3.2. Market Share Comparison, By Region. 25
                3.1.3.3. Y-o-Y growth Comparison, By Region. 25

To be Continue...............

The growth of the global market for lung cancer diagnostics is primarily attributed to increasing developments in lung cancer-specific biomarkers. These diagnostic tools are expected to facilitate personalized treatment approach towards lung malignancies. A number of biomarkers exist in the research pipeline. In the recent past, Epigenomics AG launched a new test based on blood utilizing DNA methylation biomarkers, whose developments are in the process. The initial results obtained from these tests have promised early diagnosis of lung cancer. Such incidences are expected to increase demand for lung cancer diagnostics across the globe.

The report on the global market for lung cancer discusses such key factors that govern the economics of lung cancer diagnostics across the globe. Some of the key influences for the growth of global lung cancer diagnostics market include:

  • rising presence of carcinogenic elements in common consumables
  • surging exposure to toxic substances in factories & industrial settings
  • lack of awareness related to causes, symptoms, and preventive measures for lung cancer
  • high healthcare costs, deterring lung cancer patients from seeking optimum diagnosis

Increasing Awareness Programs for Lung Cancer to Drive Growth of the Market

A number of awareness programs associated with lung cancer and its related symptoms have been initiated in order to enhance the diagnosis and screening rates of individuals with high risks of developing lung malignancies. For example – In the United Kingdom, November is considered to be the lung cancer awareness month, and is supported by Roy Castle Lung Cancer Foundation. Such initiatives help in raising awareness about early detection and diagnosis of lung cancer.

Key market players included in Fact.MR’s report are Illumina, Inc., Thermo Fischer Scientific, Inc., Quest Diagnostics Incorporated, NanoString Technologies, Inc., Myriad Genetics, Inc., Roche Holding AG, Abbott Laboratories, QIAGEN N.V., NeoGenomics Laboratories, Inc., and Danaher Corporation.

For More Information Send Enquiry:

https://www.factmr.com/connectus/sample?flag=AE&rep_id=49

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us

Fact.MR

11140 Rockville Pike

Suite 400

Rockville, MD 20852

United States

Email: sales@factmr.com

Web: https://www.factmr.com/

Read Full PR:

https://www.factmr.com/media-release/35/global-lung-cancer-diagnostics-market